Citadel Advisors’s Forte Biosciences FBRX Stock Holding History

Citadel Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8	Closed	-$164	–	14797
2023 Q4	$164	Buy	8 +4	+100%	+$56	﹤0.01%	14110
2023 Q3	$66	Hold	4	–	–	﹤0.01%	14177
2023 Q2	$104	Hold	4	–	–	﹤0.01%	14221
2023 Q1	$101	Sell	4 -72	-95%	-$1.81K	﹤0.01%	14587
2022 Q4	$1.9K	Buy	+76	New	+$1.95K	﹤0.01%	14402
2022 Q1	–	Sell	-912	Closed	-$49K	–	13878
2021 Q4	$49K	Sell	912 -5,444	-86%	-$366K	﹤0.01%	13261
2021 Q3	$470K	Buy	+6,356	New	+$3.52M	﹤0.01%	10026
2019 Q4	–	Sell	-70	Closed	-$17K	–	9292
2019 Q3	$17K	Buy	70 +20	+40%	+$30.4K	﹤0.01%	8972
2019 Q2	$124K	Buy	+50	New	+$148K	﹤0.01%	8444

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Citadel Advisors's FBRX Position: Q1 2026 in Review

Citadel Advisors opened a new position in Forte Biosciences (FBRX) in Q1 2026: 233,369 shares worth $6.04M. The stake represents ﹤0.01% of the portfolio and ranks #4031 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in FBRX as recently as Q3 2025.

Citadel Advisors first reported a position in FBRX in Q3 2018 and has held it in 21 quarters since. The position peaked at $16.5M in Q3 2020. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

Citadel Advisors held 233,369 shares of Forte Biosciences worth $6.04M as of Q1 2026.
Forte Biosciences was a new Citadel Advisors position in Q1 2026.
Forte Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4031 holding.
Citadel Advisors first reported a position in Forte Biosciences in Q3 2018 and has held it in 21 quarters since.
Citadel Advisors's Forte Biosciences position peaked at $16.5M in Q3 2020.
68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.